Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study

doi:10.1016/j.jdermsci.2014.05.007

Randomized Controlled Trial

. 2014 Sep;75(3):201-4.

doi: 10.1016/j.jdermsci.2014.05.007. Epub 2014 Jun 4.

Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study

Nemoto Osamu¹, Nagashima Hirotaka², Sayama Koji³, Takazawa Kenji⁴

Affiliations

¹ Kojinkai Sapporo Skin Clinic, H&B plaza building 5F, S3 w2, Chuo-ku, Sapporo Hokkaido, 060-0063, Japan. Electronic address: osamu.nemo@gmail.com.
² Yanagibashi-Clinical Trial Center, Yanagibashi Hospital, Tokyo, Japan. Electronic address: nagashima@y-ctc.com.
³ Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan. Electronic address: sayama@m.ehime-u.ac.jp.
⁴ Shinanozaka Clinic, Medical Corporation Shinanokai, Tokyo, Japan. Electronic address: k-takazawa@shinanozaka-clinic.jp.

PMID: 24957501
DOI: 10.1016/j.jdermsci.2014.05.007

Randomized Controlled Trial

Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study

Nemoto Osamu et al. J Dermatol Sci. 2014 Sep.

. 2014 Sep;75(3):201-4.

doi: 10.1016/j.jdermsci.2014.05.007. Epub 2014 Jun 4.

Authors

Nemoto Osamu¹, Nagashima Hirotaka², Sayama Koji³, Takazawa Kenji⁴

Affiliations

¹ Kojinkai Sapporo Skin Clinic, H&B plaza building 5F, S3 w2, Chuo-ku, Sapporo Hokkaido, 060-0063, Japan. Electronic address: osamu.nemo@gmail.com.
² Yanagibashi-Clinical Trial Center, Yanagibashi Hospital, Tokyo, Japan. Electronic address: nagashima@y-ctc.com.
³ Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan. Electronic address: sayama@m.ehime-u.ac.jp.
⁴ Shinanozaka Clinic, Medical Corporation Shinanokai, Tokyo, Japan. Electronic address: k-takazawa@shinanozaka-clinic.jp.

PMID: 24957501
DOI: 10.1016/j.jdermsci.2014.05.007

No abstract available

PubMed Disclaimer

Cited by

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6. Cochrane Database Syst Rev. 2023. PMID: 37436070 Free PMC article. Review.
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2023 Jul 12;7:CD011535. doi: 10.1002/14651858.CD011535.pub6. PMID: 35603936 Free PMC article. Updated.
Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T. Jeon C, et al. Hum Vaccin Immunother. 2017 Oct 3;13(10):2247-2259. doi: 10.1080/21645515.2017.1356498. Hum Vaccin Immunother. 2017. PMID: 28825875 Free PMC article. Review.
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2021 Apr 19;4:CD011535. doi: 10.1002/14651858.CD011535.pub4. PMID: 31917873 Free PMC article. Updated.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study

Affiliations

Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study

Authors

Affiliations

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical